Duopharma bags RM225mil MoH insulin contracts, backed by Biocon's Johor facility


Biocon Plant located in Iskandar Puteri Johor.

KUALA LUMPUR: Duopharma Biotech Bhd has secured over RM225mil worth of insulin supply contracts from the Health Ministry, with long-time partner Biocon Limited supplying the products from its manufacturing facility in Johor.

The contracts were awarded to Duopharma's wholly owned subsidiary, Duopharma (M) Sdn Bhd, and cover recombinant human insulin, insulin glargine and insulin aspart for public healthcare facilities nationwide.

In a statement, the pharmaceutical company said the contracts comprise a three-year agreement worth about RM155.27mil for recombinant human insulin, as well as two separate two-year contracts valued at approximately RM18mil for insulin glargine and RM52.5mil for insulin aspart.

Under the agreements, Biocon's Malaysian subsidiary, Biocon Sdn Bhd, will supply the insulin products to Duopharma's wholly owned subsidiary, Duopharma (M).

The companies said the collaboration aligns with the government's objectives under the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030) to strengthen healthcare resilience and ensure a stable supply of essential medicines.

Duopharma group chief executive officer Wan Amir-Jeffery Wan Abdul Majid said the latest awards marked a decade of collaboration between the two companies and underscored the importance of strengthening domestic pharmaceutical manufacturing capabilities.

"It is more critical than ever to have robust domestic pharmaceutical manufacturing capacity to safeguard patient access to essential medicines, strengthening national medicine security and achieving healthcare self-reliance for the country," he said.

Meanwhile, Biocon chief executive officer and managing director Shreehas Tambe said Malaysia has been central to the company's insulin business for more than a decade, supported by its integrated insulin manufacturing facility in Johor, which it described as the largest in Asia.

“Our Johor operations enable us to deliver insulin at scale, expanding patient access in Malaysia and around the world. This reinforces our strategy to address growing healthcare needs while advancing our mission of making life-changing medicines affordable and accessible to patients everywhere.”

Biocon Sdn Bhd site head Joe Sian said the partnership with Duopharma has helped expand access to insulin therapies in Malaysia, where an estimated 4.75 million people are living with diabetes.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Doubling down on productivity
Towards a true Silicon Valley
Growth holds, risks loom
MISC’s RM3bil Yinson gamble
Ringgit expected to trade with slight positive bias next week
118 Mall celebrates year-end festivities with the Living Storybook
Timber's new twist
Coach, Ralph Lauren defy China slump�
Malaysia’s 3Q26 property reality check
Old drains and water strains

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read